Skip to content

The efficacy of combination of risperidone and fluoxetine in obsessive compulsive patients

Study of efficacy of risperidone addition to fluoxetine in obsessive compulsive patients

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201103083010N2
Enrollment
60
Registered
2011-04-18
Start date
2010-09-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-compulsive disorder. Anxiety disorder

Interventions

Intervention 1: Intervention group: risperidone is started at 0.5 mg/d in the first week and then is elevated to 1 mg/d in the second week and is continued until the end of the third month. Interventi
Treatment - Drugs
Placebo
Intervention group: risperidone is started at 0.5 mg/d in the first week and then is elevated to 1 mg/d in the second week and is continued until the end of the third month.
Control group: identical to that of risperidone.

Sponsors

Vice-chancellor for research, Kermanshah University of Medical Sciences and Health Services
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: obsessive compulsive disorder, New case , age>18, age16. Exclusion criteria: substance abuse, comorbid of psychotic disorder, suicidal ideation, Yale Brown rating.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Response to treatment. Timepoint: Before treatment, 6weeks after treatment , 12weeks after treatment. Method of measurement: Obsessive compulsive qustioner (Y-Bocs).

Secondary

MeasureTime frame
Clinical side effects. Timepoint: 6 and 12 weeks after treatment. Method of measurement: According to patients report.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Fahimeh Jahandar Lashaki

Farabi Hospital of Kermanshah

fh.jahandar@yahoo.com+98 83 1826 1046

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026